Phase II trial updates underpin benefit of efruxifermin for NASH
16 Jul 2021
byAudrey Abella
In individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) with fibrosis, the reductions in liver fat content (LFC) with efruxifermin correlated with improvements in markers of liver injury, fibrosis, metabolic parameters, and histologic features, according to updates from the phase IIa BALANCED study presented at ILC 2021.
